MUSTANG BIO, INC. Payments to Acquire Held-to-maturity Securities
MUSTANG BIO, INC. (MBIO) reported Payments to Acquire Held-to-maturity Securities of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2020-03-16
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for fiscal 2018 was $52.50M, a 14.13% increase from fiscal 2017.
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for fiscal 2017 was $46.00M.
- MUSTANG BIO, INC. payments to acquire held-to-maturity securities for fiscal 2016 was $0.00.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 10 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $0.00 derived: sum of 2 quarters · filed 2020-03-16 | $0.00 derived: sum of 3 quarters · filed 2020-03-16 | $0.00 10-K · filed 2020-03-16 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | $5.00M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | $5.00M derived: sum of 3 quarters · filed 2020-03-16 | $17.50M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-10 | $5.00M derived: sum of 2 quarters · filed 2020-03-16 | $17.50M derived: sum of 3 quarters · filed 2020-03-16 | $27.50M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $17.50M derived: sum of 2 quarters · filed 2020-03-16 | $27.50M derived: sum of 3 quarters · filed 2020-03-16 | $52.50M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $22.50M derived: sum of 2 quarters · filed 2019-11-12 | $47.50M 10-Q · filed 2019-11-12 | $59.41M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $35.00M 10-Q · filed 2019-08-09 | $46.91M derived: sum of 3 quarters · filed 2019-08-09 | $60.96M derived: sum of 4 quarters · filed 2019-08-09 | |
| 2018-03-31 | $25.00M 10-Q · filed 2019-05-10 | $36.91M derived: sum of 2 quarters · filed 2019-05-10 | $50.96M derived: sum of 3 quarters · filed 2019-05-10 | $71.00M derived: sum of 4 quarters · filed 2019-05-10 | |
| 2017-12-31 | $11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $25.96M derived: sum of 2 quarters · filed 2019-03-18 | $46.00M derived: sum of 3 quarters · filed 2019-03-18 | $46.00M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $14.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $34.09M derived: sum of 2 quarters · filed 2018-11-13 | $34.09M 10-Q · filed 2018-11-13 | $34.09M derived: sum of 4 quarters · filed 2018-11-13 | |
| 2017-06-30 | $20.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $20.04M 10-Q · filed 2018-08-13 | $20.04M derived: sum of 3 quarters · filed 2018-08-13 | $20.04M derived: sum of 4 quarters · filed 2018-08-13 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-14 | $0.00 derived: sum of 2 quarters · filed 2018-05-14 | $0.00 derived: sum of 3 quarters · filed 2018-05-14 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $0.00 derived: sum of 2 quarters · filed 2018-03-29 | $0.00 10-K · filed 2018-03-29 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-14 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |